Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
about
Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy.Effects of Low-Molecular-Weight Fucoidan and High Stability Fucoxanthin on Glucose Homeostasis, Lipid Metabolism, and Liver Function in a Mouse Model of Type II Diabetes.Low molecular weight fucoidan alleviates cardiac dysfunction in diabetic Goto-Kakizaki rats by reducing oxidative stress and cardiomyocyte apoptosis.Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFβ1 and miR-29 pathways.Predictors and prevention of diabetic cardiomyopathy.PPARs modulate cardiac metabolism and mitochondrial function in diabetes.CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts.Integrins and integrin-related proteins in cardiac fibrosis.Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.Mitochondrial dysfunction and its impact on diabetic heart.Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.GYY4137, a novel hydrogen sulfide-releasing molecule, likely protects against high glucose-induced cytotoxicity by activation of the AMPK/mTOR signal pathway in H9c2 cells.Role of biomarkers in predicting diabetes complications with special reference to diabetic foot ulcers.Pathophysiological Fundamentals of Diabetic Cardiomyopathy.Ginsenoside Rh2 Improves Cardiac Fibrosis via PPARδ-STAT3 Signaling in Type 1-Like Diabetic Rats.Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.Protective effect of angiotensin-(1-7) against hyperglycaemia-induced injury in H9c2 cardiomyoblast cells via the PI3K̸Akt signaling pathway.Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.Sodium Butyrate Controls Cardiac Hypertrophy in Experimental Models of Rats.Mitochondrial aldehyde dehydrogenase 2 deficiency aggravates energy metabolism disturbance and diastolic dysfunction in diabetic mice.Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.FP-receptor gene silencing ameliorates myocardial fibrosis and protects from diabetic cardiomyopathy.
P2860
Q30389310-09591364-DE6F-4C2E-A489-BBBE35B72F35Q33612248-32DC21B0-D6AC-43A7-BFF8-84DD46314070Q34708259-7FBF41BC-CD70-44A9-A8E9-D88D8610439CQ36681664-5AA9267C-6D22-4C2F-A46A-5B169A29FE1CQ36776922-57EF2161-C816-4943-BDFB-93396A92D942Q37576286-389E8E85-DC81-4763-AC7E-9E98F1675414Q37581707-B1D04134-3C4B-4565-A622-ADDFB2EAAC56Q38631821-B23747A9-9CB7-4AC0-96A1-D03EA3866E51Q38752958-5A926749-2D89-4A4E-AA14-CCFEFAF3CC0BQ38946122-C36678BF-CD86-485D-A026-F125365EAE42Q38972184-093DCD3E-1754-472C-B4EF-96469C6485A4Q39038826-1540FDF4-6257-4A3D-B9C6-712B30407DA5Q39192355-EC42F2F4-BE28-445E-838A-402288476B4AQ39195672-1778BDD4-E8C9-4B07-9296-458E2DA4E1A4Q41181423-87A740F4-579C-4B60-9D6F-BCE7C783CBC8Q42376648-8DD69FFD-B87E-456C-9ADC-970E5DEAFC13Q47246750-B9012256-35D5-43D7-BC58-EC88195FD0CAQ48043450-270DC236-F235-47BC-B585-C89B2F530B43Q48302650-FDCC3FE6-3290-459C-87D6-E43214C2B880Q51596254-694416D0-29DD-4325-A3E8-995F44D5ED50Q53714172-F4EA75A0-06A6-45CC-A6C3-145C8CFCF839Q54379423-9094E425-F431-459C-B591-1C00ACC3D0BC
P2860
Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
@en
type
label
Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
@en
prefLabel
Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
@en
P2860
P356
P1476
Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
@en
P2093
P2860
P304
P356
10.1177/0960327112450885
P577
2012-11-22T00:00:00Z